SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case

SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case

The article highlights the course of long-term SARS-CoV-2 infection in a patient with a secondary immunodeficiency developed with B-cell-depleting therapy of the underlying disease. Analysis of the intrapatient virus evolution revealed an inpatient S:G75A mutation that alters the 72GTNGTKR78 motif o...

Full description

Bibliographic Details
Main Authors:	Olgo A. Mukhina, Daria S. Fomina, Vasiliy V. Parshin, Vladimir A. Gushchin, Inna V. Dolzhikova, Alexey M. Shchetinin, Dmitriy M. Chudakov, Evgeniia Alekseeva, Dmitriy Korostin, Georgii A. Bazykin, Galya Klink, Denis Yu. Logunov, Maryana A. Lysenko
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-11-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	immunodeficiency b-cell depletion rituximab coronavirus evolution covid-19 sars-cov-2 human immunoglobulin convalescent plasma normal human intravenous immunoglobulin
Online Access:	http://dx.doi.org/10.1080/21645515.2022.2101334

Similar Items

Hyperimmune Globulins for the Management of Infectious Diseases
by: Ilaria Pati, et al.
Published: (2023-07-01)

Steroid-Resistant immune thrombocytopenia: Challenges and solutions
by: Abhishekh Basavarajegowda, et al.
Published: (2021-01-01)

Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature
by: Sunha Choi, et al.
Published: (2021-09-01)

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy
by: Hayder Al-Momen, et al.
Published: (2020-07-01)

Long-term results of rituximab–intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy
by: Ayse Oktem, et al.
Published: (2017-01-01)

Successful treatment of recalcitrant juvenile pemphigus foliaceus with intravenous immunoglobulin and rituximab
by: Hock Gin Teo, et al.
Published: (2022-01-01)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
by: Jack Arnold, et al.
Published: (2022-01-01)

Plasma therapy: a passive resistance against the deadliest
by: Anita Hansda, et al.
Published: (2022-04-01)

Possibility to Obtain Anti-Athrax Human Immunoglobulin for Intravenous Injection
by: V. Yu. Dolmatov, et al.
Published: (2008-04-01)

Convalescent (Immune) Plasma Followed by Intravenous Immunoglobulin Infusion in an Adolescent with Severe COVID-19
by: Öner Özdemir, et al.
Published: (2021-08-01)

Seroplrevalence of <i>Anaplasma phagocytophilum</i> and <i>Ehrlichia</i> sp. among people affected by tick bites
by: N. A. Liapunova, et al.
Published: (2022-12-01)

Polymyositis following varicella and mumps infection in adults: report of two cases
by: F. Masini, et al.
Published: (2023-12-01)

Infection Risk, Mortality, and Hypogammaglobulinemia Prevalence and Associated Factors in Adults Treated with Rituximab: A Tertiary Care Center Experience
by: Moustafa S. Alhamadh, et al.
Published: (2023-10-01)

The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab
by: Marie-Laure Golinski, et al.
Published: (2022-03-01)

Immunoglobulin abnormalities are frequent in patients with lupus nephritis
by: M. J. Cuadrado, et al.
Published: (2019-08-01)

Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives – current situation and perspectives
by: Adriana Tamburello, et al.
Published: (2020-04-01)

Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients
by: MEENU BAJPAI, et al.
Published: (2022-09-01)

Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia
by: Nina Nurarifah, et al.
Published: (2021-11-01)

Effective presence of antibodies against common human coronaviruses in immunoglobulin medicinal products
by: José María Díez, et al.
Published: (2022-03-01)

Antibodies, their structure and function /
by: 396192 Steward, Michael W.
Published: (1984)

Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
by: Ivan Krečak, et al.
Published: (2023-01-01)

Low Incidence of Acute Antibody-Mediated Rejection after HLA Desensitization in Living Donor Kidney Transplant Recipients
by: Constantino Fernández Rivera, et al.
Published: (2022-11-01)

Síndrome opsoclonus-mioclonus-ataxia: relato de caso
by: Rosiane Souza Rosse, et al.
Published: (2023-06-01)

Polyclonal Immunotactoid Glomerulopathy Associated with Monoclonal Gammopathy of IgM Type and Underlying Plasmacellular Disease: Successful Treatment with Rituximab Alone
by: Wolfgang Neukirchen, et al.
Published: (2022-04-01)

Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
by: Massimo Franchini, et al.
Published: (2024-02-01)

Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia
by: Heba K. Nabih
Published: (2021-02-01)

Epitope-Specific Response of Human Milk Immunoglobulins in COVID-19 Recovered Women
by: Tatyana V. Bobik, et al.
Published: (2021-06-01)

Handbook of therapeutic antibodies : technologies, emerging developments and approved therapeutics /
by: Dubel, Stefan
Published: (2010)

Continuous increase of immunoglobulin therapy in Iceland
by: Valgeir Steinn Runólfsson, et al.
Published: (2022-12-01)

EFFECTS OF IVIG TREATMENT UPON LOCAL AND GENERAL IMMUNITY STATE IN THE PATIENTS WITH ACUTE EPIGLOTTITIS
by: A. V. Savchenko, et al.
Published: (2014-07-01)

Current biologics in treatment of pemphigus foliaceus: a systematic review
by: Caden A. Carver, et al.
Published: (2023-10-01)

Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study
by: Anna Vanoverschelde, et al.
Published: (2023-12-01)

COVID‐19 infection in CVID patients: What we know so far
by: Niels Weifenbach, et al.
Published: (2021-09-01)

Immunoglobulin G4-related disease mimicking lymphoma: Challenging to diagnose
by: Aria Namiq Chaqmachi, et al.
Published: (2023-01-01)

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
by: María Eva Mingot-Castellano, et al.
Published: (2023-10-01)

Refractory Fulminant Acute Disseminated Encephalomyelitis (ADEM) in an Adult
by: Jose eBiller, et al.
Published: (2014-12-01)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
by: Joanna Tieu, et al.
Published: (2021-05-01)

Adult-onset immunoglobulin A vasculitis
by: Megha Amarapur, et al.
Published: (2021-01-01)

Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi
by: Sei Adachi, et al.
Published: (2022-02-01)

High level of IgG4 in a patient with Extensive pulmonary involvement
by: Mohammad Hasan Bemanian, et al.
Published: (2021-06-01)